Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer

被引:16
作者
Berghmans, T
Meert, AP
Martin, B
Ninane, V
Sculier, JP
机构
[1] Hop St Pierre & Erasme, Dept Pneumol, Brussels, Belgium
[2] Inst Jules Bordet, Dept Crit Care & Thorac Oncol, B-1000 Brussels, Belgium
关键词
epidermal growth factor receptor; nonsmall cell lung cancer; prognostic factors; staging;
D O I
10.1183/09031936.05.00060804
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
New biological factors have not been extensively studied in stage III nonsmall cell lung cancer (NSCLC). The aim of the present retrospective study was to determine the role of epidermal growth factor receptor (EGF-R) as a prognostic factor in stage III NSCLC, in addition to the stage and other known clinical factors. Clinical characteristics were retrieved from the patients' charts. Membrane immunostaining for EGF-R was evaluated by three independent observers. The Cox multivariate model, including all variables with a p-value of <0.2 in univariate analysis, was used to assess the impact of clinical and biological factors on patients survival. Between January 1987 and July 2002, 99 assessable stage III NSCLC patients were included in the study. A total of 23 patients were positive for EGF-R (squamous 39.6% versus nonsquamous 7.8%). In multivariate analysis, only three factors were statistically significantly associated with survival: performance status, surgery and creatinine. In conclusion, good performance status, surgical resection and creatinine were found to be independent favourable prognostic factors for survival in a retrospective analysis of stage III nonsmall cell lung cancer, while epidermal growth factor receptor was not even in the univariate analysis.
引用
收藏
页码:329 / 335
页数:7
相关论文
共 31 条
[1]   Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications [J].
Andre, F ;
Grunenwald, D ;
Pignon, JP ;
Dujon, A ;
Pujol, JL ;
Brichon, PY ;
Brouchet, L ;
Quoix, E ;
Westeel, V ;
Le Chevalier, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2981-2989
[2]   Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy [J].
Berghmans, T ;
Lafitte, JJ ;
Thiriaux, J ;
VanHoutte, P ;
Lecomte, J ;
Efremidis, A ;
Koumakis, G ;
Giner, V ;
Richez, M ;
Corhay, JL ;
Wackenier, P ;
Lothaire, P ;
Mommen, P ;
Ninane, V ;
Sculier, JP .
LUNG CANCER, 2004, 45 (03) :339-348
[3]   CLINICAL-SIGNIFICANCE OF INTRANODAL AND EXTRANODAL GROWTH IN LYMPH-NODE METASTASES OF NONSMALL CELL LUNG-CANCER [J].
BOLLEN, ECM ;
THEUNISSEN, PHMH ;
VANDUIN, CJ ;
DRENTH, BM ;
VANNOORD, JA ;
BLIJHAM, GH .
SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1994, 28 (3-4) :97-102
[4]   Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer [J].
Cappuzzo, F ;
Magrini, E ;
Ceresoli, GL ;
Bartolini, S ;
Rossi, E ;
Ludovini, V ;
Gregorc, V ;
Ligorio, C ;
Cancellieri, A ;
Damiani, S ;
Spreafico, A ;
Paties, CT ;
Lombardo, L ;
Calandri, C ;
Bellezza, G ;
Tonato, M ;
Crinò, L .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) :1133-1141
[5]   A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers [J].
D'Amico, TA ;
Massey, M ;
Herndon, JE ;
Moore, MB ;
Harpole, DH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (04) :736-742
[6]  
De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO
[7]  
2-7
[8]   Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].
Giaccone, G ;
Herbst, RS ;
Manegold, C ;
Scagliotti, G ;
Rosell, R ;
Miller, V ;
Natale, RB ;
Schiller, JH ;
von Pawel, J ;
Pluzanska, A ;
Gatzemeier, M ;
Grous, J ;
Ochs, JS ;
Averbuch, SD ;
Wolf, MK ;
Rennie, P ;
Fandi, A ;
Johnson, DH .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784
[9]   Non-small cell lung cancer: Clinical value of new biological predictors [J].
Graziano, SL .
LUNG CANCER, 1997, 17 :S37-S58
[10]   Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 [J].
Herbst, RS ;
Giaccone, G ;
Schiller, JH ;
Natale, RB ;
Miller, V .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :785-794